Rettocolite Ulcerosa: nuovo Sinbiotico a base di Lactobacillus GG migliora sintomi e qualità di vita

Ulcerative Colitis: A Next-Generation Synbiotic Based on Lactobacillus Rhamnosus GG Improves Symptoms and Quality of Life Chronic inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, have a significant impact on the quality of life of those who suffer from them. Since they often begin at a young age, they also severely impair social functioning. Over the years, therapeutic innovation has allowed for better control of symptoms and inflammation, but many unmet needs remain—both clinical and psychological—to be addressed. A recent study conducted by the Gemelli Hospital in Rome used a next-generation synbiotic, the result of Omega Pharma's advanced research, in combination with traditional therapies to modulate the microbiota in patients with ulcerative colitis. The results demonstrated significant improvements in both psychological and general well-being scores and gastrointestinal symptoms. We discussed this with: Loris Lopetuso, Gastroenterologist, Fondazione Policlinico A. Gemelli IRCCS Emanuele Rinninella, Nutritionist, Fondazione Policlinico A. Gemelli IRCCS Topics covered: The current treatment scenario for ulcerative colitis and what needs to be addressed. What role does an unbalanced microbiota, and therefore dysbiosis, play in ulcerative colitis? What are the characteristics of supplements, including prebiotics, postbiotics, probiotics, and new synbiotics? What are the differences, and specifically, what are synbiotics? The study with Lactobacillus Rhamnosus GG with the addition of Boswellia, Quercetin, Bromelain, Vitamin D3, Inulin, FOS, and Tryptophan: which patients did it enroll and what did it demonstrate in terms of disease activity, maintenance of remission, and quality of life? What other frontiers of study are opening up with the new category of synbiotics? What are they being studied in?